Patient Education
Strengthening Patient Voices at WECAN Academy 2026
DiCE advocates joined more than 100 patient leaders from 34 countries at WECAN Academy 2026, gaining new advocacy skills, sharing European initiati...
KI-COMPASS: Using AI to Transform Follow-Up Care After Gastroesophageal Cancer
KI-COMPASS is exploring how artificial intelligence, wearable technology and clinical data can personalise follow-up care after gastroesophageal ca...
New Patient-Led Survey Explores What Meaningful Cancer Support Really Looks Like
Every word matters. Take part in this patient-led survey exploring what meaningful cancer support truly looks like. Share your experience and help ...
What ASCO 2026 Means for People Living with Gastric Cancer
New treatment advances presented at ASCO 2026 are bringing fresh hope to people living with gastric cancer. Experts highlighted promising results f...
BREAKWATER Study Highlights the Growing Impact of Personalised Medicine in Colorectal Cancer
At this year’s ASCO Annual Meeting, researchers presented new results from the Phase III BREAKWATER trial, providing further evidence that a ...
EMERALD-3 Brings New Hope for People with Unresectable Liver Cancer
New results from the Phase III EMERALD-3 study offer encouraging news for people with unresectable liver cancer. By combining immunotherapy, target...
Structured Exercise Helps Colon Cancer Patients Live Longer While Lowering Healthcare Costs
The American Society of Clinical Oncology (ASCO) Annual Meeting continues to be one of the most important events for cancer research, bringing toge...
New Hope in Pancreatic Cancer Treatment: Updated Results from the RASolute 302 Trial
Pancreatic cancer remains one of the most challenging cancers to treat. In most cases, it is diagnosed at an advanced stage and is initially treate...
New Targeted Pill Shows Promise for Advanced Pancreatic Cancer
A new targeted treatment for advanced pancreatic cancer has shown encouraging early results in a major clinical trial. The experimental pill, darax...
POLAR Trial Offers New Hope for Some Patients With Metastatic Pancreatic Cancer
Early findings from the Phase 2 POLAR trial suggest that combining pembrolizumab and olaparib may benefit selected patients with metastatic pancrea...